Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $455.24M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 2.08M
Average 0.69M
STTK Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Shattuck Labs, Inc.NASDAQ: STTK
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.42M rose 40.3% year over year, ahead of the -12.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 50.4% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.
Context
- Stock-based compensation amounted to 699.5% of revenue in FY2025, up 532.6 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +40.3% holds above the trailing-twelve-month pace of -12.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 7M USD
- Year-over-year change
- -26.7%
- 4-year CAGR
- +6.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7M | -26.7% |
| FY2024 | 2024-12-31 | 9.55M | +37.6% |
| FY2023 | 2023-12-31 | 6.94M | +7.4% |
| FY2022 | 2022-12-31 | 6.46M | +18.2% |
| FY2021 | 2021-12-31 | 5.47M | — |
Stock-Based Compensation vs competitors
How STTK compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -12.5% is the 5th highest of 10, against a peer median of -13.7%.
- Stock-based compensation amounts to 768.9% of revenue for STTK, versus a peer median of 12.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.79B USD | -27809.6% | +824.6% | — | |
| LTM Sep 2026 | $46.65M USD | -42.2% | -9.8% | 12.3% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥26.02M CNY | +1.1% | -74.4% | — |
| LTM Jun 2026 | $17.93M USD | +869.7% | -39.7% | — | |
| LTM Mar 2026 | $16.18M USD | +309.7% | +51.1% | 136.2% | |
| LTM Mar 2026 | $7.69M USD | -12.5% | +2.7% | 768.9% | |
| LTM Mar 2026 | $6.81M USD | -13.7% | -16.3% | 3.0% | |
| LTM Mar 2026 | $6.38M USD | -39.9% | -18.4% | — | |
| LTM Sep 2026 | $4.19M USD | +122.7% | +4.3% | — | |
| LTM Mar 2026 | $1.19M USD | -32.6% | -22.8% | — | |
| Peer median (excluding STTK) | — | -13.7% | -16.3% | 12.3% | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Depreciation & Amortization | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| Deferred Income Tax | 3.04M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.47M | 6.46M | 6.94M | 9.55M | 7M |
| Change in Working Capital | (23.55M) | (4.46M) | (4.1M) | 3.02M | (785K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.87M | (2.84M) | (5.63M) | 832K | (318K) |
| Other Working Capital | (31.41M) | (1.62M) | 1.53M | 2.19M | (467K) |
| Other Non-Cash Items | 1.52M | 2.38M | (816K) | (1.5M) | (971K) |
| Operating Cash Flow | (57.12M) | (94.5M) | (81.23M) | (60.52M) | (39.88M) |
| Capital Expenditures | (7.93M) | (11.61M) | (407K) | (59K) | (71K) |
| Acquisitions (Net) | 2.52M | 104K | 0 | 0 | 0 |
| Purchases of Investments | (204.09M) | (132.38M) | (79.73M) | (93.55M) | (43.42M) |
| Sales of Investments | 201.58M | 193.33M | 191M | 85.1M | 35.6M |
| Other Investing Activities | (2.52M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (10.44M) | 49.44M | 110.86M | (8.51M) | (7.89M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.93M | 171K | 48.67M | (17K) | 44.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (53K) | 804K | (65K) |
| Financing Cash Flow | 1.93M | 171K | 48.62M | 787K | 44.57M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (65.63M) | (44.89M) | 78.25M | (68.24M) | (3.2M) |
| Free Cash Flow | (65.04M) | (106.11M) | (81.64M) | (60.57M) | (39.95M) |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.